Pilot clinical trial, controlled and randomized, Phase III, to evaluate security and efficacy of oral specific immunotherapy in HIV infected patients who suffer from grass pollen allergy.

AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2012年3月8日最近更新: 2014年2月3日

适应症

试验速览

暂无简介。

•1) HIV-positive adults between 18 and 60 years in HAART therapy for at least 6 months
•2) Diagnosis of allergy to grass (with skin prick tests and / or RAST)
•3) Diagnosis of rhinitis persistent moderate / severe according to the ARIA classification
•4) Diagnosis of persistent mild intermittent asthma according GINA classification
•5) CD4> 400 stable for at least 6 months
•6) VL <37 copies of at least 6 months.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1) Prior treatment with specific immunotherapy
•2) allergy to perennial allergens (Molds, mites and animals when exposed to the animal)
•3) patients with chronic diseases (infectious, autoimmunity, cancer, heart or kidney diseases) or ongoing pregnancy
•4) Chronic pharmacological treatment with steroids and / or immunosuppressive
•5) diseases of the oral cavity
•6) serious bronchial asthma (GINA classification).

发起方

AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)